Home/Pipeline/PD01 (acquired by AC Immune)

PD01 (acquired by AC Immune)

Parkinson's Disease

Phase 1Acquired/Partnered

Key Facts

Indication

Parkinson's Disease

Phase

Phase 1

Status

Acquired/Partnered

Company

AFFiRiS

About AFFiRiS

AFFiRiS is an Austrian biotechnology company pioneering a vaccine-like immunotherapy platform, AFFITOME®, to treat chronic diseases by targeting pathological proteins. Its most advanced programs target alpha-synuclein for Parkinson's disease and PCSK9 for hypercholesterolemia, with multiple assets having reached Phase 1 clinical trials. The company operates as a private entity, advancing its pipeline through strategic partnerships and out-licensing deals, such as the acquisition of its alpha-synuclein programs by AC Immune in 2021.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Cardiovascular/Metabolic

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active